Skip to content
  • twitter
  • linkedin
  • onxeo
  • SUBSCRIBE TO OUR NEWS
  • EN
  • FR
  • CONTACT
Onxeo

Onxeo

Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions.

  • COMPANY
    • Profile
    • Executive Committee
    • Board of Directors
    • Join us
    • Contact us
  • SCIENCE
    • DNA Damage Response
    • platON™
    • Collaborations
  • PRODUCTS
    • DDR Pipeline
    • AsiDNA™
    • OX401
    • Other
  • INVESTORS
    • Regulated Information
      • Press Releases
      • Registration documents
      • Financial Information
      • Shares & Voting Rights
      • Share Repurchase/ Liquidity Agreement
      • Financial operations
    • Governance
      • Board Committees & Regulations
      • Directors’ Disclosures
      • Bylaws
    • Shareholder Resources
      • General Meetings
      • Financial Calendar
      • Stock Information
      • Shareholders’ Letters
    • Investor Relations
  • NEWS & EVENTS
    • Press Releases
    • Events & Presentations
    • Shareholder Letters
    • Media

Category: Press releases

Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a phase 1b/2 Clinical Trial of AsiDNA™ in combination with radiotherapy for Treatment of High-Grade Glioma Relapse in Children

02/04/202102/04/2021

This study is supported by a grant from the European Fight Kids Cancer program[1]   Paris (France), February 4, 2021 […]

Onxeo publishes Letter to Shareholders and provides update on its developments

02/02/202102/02/2021

Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]

Onxeo Obtains Non-Dilutive Financing of 5 Million Euros in the Form of State Guaranteed Loans

01/28/202102/01/2021

This financing extends the Company’s cash horizon to the 3rd quarter of 2022   Paris (France), January 28, 2021 – […]

2020 – Full-year report on the liquidity contract

01/08/202101/14/2021

2020 Full-year report on the liquidity contract

Onxeo to Attend Key Investor and Scientific Conferences

01/11/202101/10/2021

Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Announces its Financial Agenda for 2021

01/07/202101/08/2021

Paris (France), January 7, 2021 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020

12/10/202012/10/2020

Paris (France), December 10, 2020 – 6 pm CET – Onxeo S.A. (ISIN: FR0010095596), (“Onxeo” or “the Company”), a clinical-stage […]

Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results

11/09/202011/09/2020

The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients […]

Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors

10/22/202010/22/2020

This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient […]

Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan

10/21/202010/21/2020

Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer […]

Publication of the 2019 Half-Yearly Financial Report

07/31/201909/29/2020

Paris (France), July 31, 2019 – 7.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]

Publication of the 2020 Half-Yearly Financial Report

09/29/202009/29/2020

Paris (France), September 29, 2020 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]

Onxeo reports its financial results for the first half of 2020 and provides an update on its activities

09/17/2020

The cash position of €19.6 million, which was strengthened in the first half of the year by two strategic transactions, […]

Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020

09/08/202009/08/2020

Paris (France), September 8, 2020 – 7:00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States

09/03/202009/03/2020

This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]

Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer

08/27/202008/27/2020

DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]

Transfer of the listing of Onxeo securities from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility

07/29/202007/30/2020

Paris (France), July 29, 2020 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Announces Approval of the REVocan Study By Regulatory Authorities

05/29/202007/09/2020

The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian […]

Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux

07/03/202007/09/2020

July 3, 2020 – 6:00 pm CEST   Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]

Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties

06/25/202006/24/2020

Paris (France), June 25, 2020 – 7.00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020

06/22/202006/19/2020

Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells   […]

Onxeo: report on the Extraordinary General Meeting of June 19, 2020

06/19/202006/19/2020

Paris (France), June 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo announces a capital increase of €7.3 million by private placement to Invus and Financière de la Montagne, the Company’s historical shareholder

06/09/202006/08/2020

The funds raised will accelerate the development of Onxeo’s programs, and extend its cash runway into Q1 2022                 Paris […]

Onxeo announces that the Shareholders’ Meeting of May 29, 2020 has approved all ordinary resolutions

05/29/202005/29/2020

The Extraordinary General Meeting will be held on June 19, 2020 on the second call   Paris (France), May 29, […]

Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation

05/27/202005/29/2020

Paris (France), May 27, 2020 – 8.45 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi

05/19/202005/19/2020

Paris (France), Mai 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Publication of the 2019 Universal Registration Document

04/27/202005/07/2020

Paris (France), April 27, 2020 – 7.00 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

Onxeo’s Joint General Meeting in camera on May 29, 2020: availability of preparatory documents and live webcast login information

05/07/202005/07/2020

Paris (France), May 7, 2020 – 7:30 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

Onxeo Reports Full-Year 2019 Financial Results and Provides Business Update

04/17/202004/23/2020

Cash position of €5.7 million at December 31, 2019, combined with $6.6 million from new agreement with Acrotech, provide extended […]

Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC

04/06/202004/06/2020

This transaction completes Onxeo’s strategic transition to a company solely focused on DNA Damage Response (DDR) activities in oncology $6.6m […]

Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020

02/27/202004/01/2020

Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Will Publish Its Annual Results on April 17, 2020

03/27/202004/01/2020

The Annual General Meeting will be held on May 29, 2020 Paris (France), March 27, 2020 – 8:30 pm CET […]

Onxeo to Present Next-Generation PARP inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020

01/28/202003/13/2020

Paris (France), January 28, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Publishes Shareholder Newsletter

01/20/202003/13/2020

Paris (France), January 20, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Announces its Financial Agenda for 2020

12/09/201903/13/2020

  Paris (France), December 9, 2019 – 05:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or […]

Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology

11/13/201903/13/2020

In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity Paris (France), November 13, 2019 […]

Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer

01/29/202003/13/2020

The REVOCAN phase 1b/2 study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to […]

Onxeo Enters into Settlement Agreement with SpePharm and SpeBio

02/11/202003/13/2020

Settlement agreement fully resolves long-lasting litigation between the parties and all related proceedings Settlement terms have no impact on Onxeo’s […]

Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.

11/05/201911/05/2019

Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment

11/04/201911/05/2019

Combination patent to be granted in the U.S. until 2036 Paris (France), November 4, 2019 – 5:45 pm CEST – […]

Onxeo, Winner of the Innov’up Leader PIA Call for Projects, Receives Funding of €495,000

10/17/201911/05/2019

The winning project aims to develop a drug candidate in immuno-oncology from the platON™ platform Funding from the French State […]

Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

10/15/201910/16/2019

Positive Safety and Activity Results from DRIIV-1 Led to Initiation of Ongoing DRIIV-1b Phase 1b Study of AsiDNA™ in Combination […]

Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform

10/14/201910/16/2019

This new patent protects in particular AsiDNA™ and its related compounds for their use in the treatment of cancer, alone […]

Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy

09/18/201910/16/2019

  Stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ […]

Publication of 2017 Registration Document

04/25/201810/08/2019

Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]

Onxeo to Present Corporate Overview at the H.C. Wainwright Annual Global Life Sciences Conference

04/09/201810/04/2019

Advancing innovation towards breakthrough cancer therapies Paris, April 9, 2018 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ […]

Onxeo Announces Initiation of DRIIV Phase I Clinical Trial of AsiDNA™ for Treatment of Advanced Solid Tumor

04/24/201810/04/2019

First patient has been dosed with AsiDNA™, Company’s first-in-class DNA Repair Inhibitor Study approved in France and Belgium, and conducted […]

Combined General Meeting on May 16, 2018

04/25/201810/04/2019

Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]

Onxeo Reports Full-Year 2017 Financial Results and Provides Business Update

03/29/201810/04/2019

Advancement of core pipeline assets on track with key development catalysts expected in 2018 First new molecule generated from platON™, […]

Meet the Onxeo Team during the 2017 J.P. Morgan Healthcare Conference

12/22/201610/03/2019

January 9-12, 2017 in San Francisco, CA  In 2016, Onxeo has achieved a number of significant milestones, positioning the Company […]

Posts navigation

Older posts

NEWS & EVENTS

  • Press Releases
  • Events & Presentations
  • Shareholder Letters
  • Media
Onxeo

> SITE MAP

> LEGAL NOTICES
> FOLLOW US

COMPANY

COMPANY


  • Profile
  • Executive Committee
  • Board of Directors
  • Join us
  • Contact us

SCIENCE

SCIENCE


  • DNA Damage Response
  • platON™
  • Collaborations

PRODUCTS

PRODUCTS


  • Pipeline
  • AsiDNA™
  • OX401
  • belinostat / Beleodaq®

INVESTORS

INVESTORS


  • Regulated Information
  • Governance
  • Shareholder Resources
  • Investor Relations

NEWS AND EVENTS

NEWS & RELEASES


  • Press Releases
  • Events & Presentations
  • NewsLetters
  • Media
SUBSCRIBE TO
OUR NEWS
CONTACT
US

ONXEO SA


49, avenue du Général Martial Valin
75015 PARIS – FRANCE
+33 (0) 1 45 58 76 00

© Copyright 2019 Onxeo
Photos : Onxeo - Design : 1sur1.net

Copyright © 2021 Onxeo All rights reserved. Theme: Flash by ThemeGrill. Powered by WordPress